 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| Another Milestone and New Lucrative Market for AXIM: Trials Begin to Treat IBS - Affects 15% of World Population |
|
 Hot Stock to Watch |
Company: AXIM® Biotechnologies, Inc. (OTCQB: AXIM)
|
Last:
Price: 13.682
Change (%): + 3.282 (31.56)
Volume: 352,162 |
 |
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) - AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum at Wageningen University in the Netherlands.
The research team previously received approval from the Medical Ethical Committee (METC) of Wageningen University to study novel treatments for patients suffering from IBS. Functional, controlled-release Hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies. The amount of the Hemp oil CBD gum is set at 50 mg CBD per serving. According to the trial protocol patients can use up to 6 chewing gums a day to control their stomach cramps, bloating, pain and other symptoms. The main study outcome is perceived pain reduction. Furthermore, the study will record general relief and change in stool frequency.
Designed by clinical investigators at Wageningen University and the AXIM Biotech team, the clinical trial will include a group of 40 patients age 18-65, diagnosed with IBS according to ROME III criteria to determine the effectiveness of CanChew Plus in alleviating IBS symptoms.
“We are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “IBS is the most common functional gastrointestinal disorder affecting 9-15% of the worldwide population, and it has no sustainable cure.”
Continue Reading |
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
